Home > Boards > US Listed > Biotechs >

Dicerna Pharmaceuticals, Inc. (DRNA)

Add DRNA Price Alert      Hide Sticky   Hide Intro
Search This Board: 
Last Post: 4/20/2017 9:52:32 AM - Followers: 5 - Board type: Free - Posts Today: 0

Dicerna Pharmaceuticals, Inc. Building 1 Suite 120 Watertown, MA 02472 United States Phone: 617-621-8097 Website: http://www.dicerna.com Dicerna Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery and development of treatments for liver diseases and cancers based on a proprietary RNA interference technology platform in the United States and internationally. The company’s development programs include DCR-PH1 for the treatment of primary hyperoxaluria 1 (PH1) through targeting the liver metabolic enzyme glycolate oxidase; and other rare inherited diseases involving disease target genes expressed in the liver, including hemophilia, porphyria, hypercholesterolemia, hemoglobinopathies, alpha-1-antitrypsin deficiency hepatocyte, inclusions, and others. It is also developing DCR-M1711 for the treatment of various cancers through targeting the MYC oncogene, a gene that causes or promotes cancer when abnormally expressed or activated, as well as a product candidate targeting the oncogene KRAS; and a second product candidate targeting an oncogene. The company has a research collaboration and license agreement with Kyowa Hakko Kirin Co., Ltd. for the research, development, and commercialization of drug delivery platforms and DsiRNA molecules for therapeutic targets, primarily in oncology; and a license agreement with City of Hope, an academic research and medical center, to manufacture, use, offer for sale, sell, and import products related to DsiRNA for the prevention and treatment of various diseases in humans. Dicerna Pharmaceuticals, Inc. was founded in 2006 and is headquartered in Watertown, Massachusetts.
Current Price
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
DRNA News: Current Report Filing (8-k) 01/08/2019 04:32:39 PM
DRNA News: Dicerna Pharmaceuticals, Inc. Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4) 01/08/2019 04:05:00 PM
DRNA News: Boehringer Ingelheim Exercises Option on Second Hepatic Disease Target from Research Collaboration with Dicerna 01/04/2019 07:00:00 AM
DRNA News: Current Report Filing (8-k) 01/04/2019 06:09:03 AM
DRNA News: Statement of Beneficial Ownership (sc 13d) 12/20/2018 03:44:31 PM
PlusOneCoin Top Posts
No plusone'd posts yet. Be the first!
#7   Domain Partners VIII, L.P. has filed a new wiltonio 04/20/17 09:52:32 AM
#6   Dicerna Pharma $DRNA has little Margin of Safety ValueInvestor15 03/21/17 06:58:12 AM
#5   +.25 !! WarChest 11/11/16 02:52:39 PM
#4   chart looking good !!! WarChest 11/11/16 10:55:19 AM
#3   Possible breakout INTL 09/30/16 10:48:32 AM
#2   * * $DRNA Video Chart 09-29-16 * * ClayTrader 09/29/16 05:04:18 PM
#1   $DRNA DD Notes ~ http://www.ddnotesmaker.com/DRNA stocktrademan 12/19/14 10:24:16 AM